QUICK POLL
Microsatellite Instability (MSI-H) in colon cancer has been associated with which of the following?
5th European Congress on Hematologic Malignancies: From Clinical Science
to Clinical Practice
February 13 - 15, 2009
Munich, Germany
Who Should Attend
This activity is designed for hematologists and oncologists in active clinical practice involved and/or interested in lymphoma, myeloma and management of related hematological disorders such as MDS in the special session of the 2009 Congress.
Objectives
After successfully completing this educational activity, participants should be able to:
- This activity is designed for hematologists and oncologists in active clinical practice involved and/or interested in lymphoma, myeloma and management of related hematological disorders such as MDS in the special session of the 2009 Congress.
- Demonstrate thorough knowledge and current clinical understanding of indolent lymphomas and
related diseases - Discuss recent advances in prognostic indicators, front-line and relapsed/refractory treatment, in addition to novel agents in chronic lymphocytic leukemia
- Evaluate chemotherapy, radioimmunotherapy, targeted therapy, and transplantation as treatment options for various stages of indolent lymphoma
- Employ current and novel strategies to improve diagnosis and treatment outcomes in aggressive non-Hodgkin’s lymphomas
- Integrate important advances in the front-line and targeted treatment in T-cell lymphomas
- Impact patient outcomes by assimilating the mechanism of action, toxicity, and therapeutic response for both current and emerging agents in MDS to determine the optimal choice of therapy
Kenneth C. Anderson, MD, MA
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Simone Boehrer, MD
Hopital Avicenne
Villejuif, France
Federico Caligaris-Cappio, MD
Università Vita-Salute San Raffaele
San Raffaele Scientific Institute
Milan, Italy
Bertrand Coiffier, MD
Hospices Civils de Lyon
Lyon, France
Daphne de Jong, MD, PhD
The Netherlands Cancer Institute
Amsterdam, Netherlands
Volker Diehl, MD, PhD
University Hospital of Cologne
Cologne, Germany
Meletios A. Dimopoulos, MD
University of Athens School of Medicine
Alexandra Hospital
Athens, Greece
Martin Dreyling, MD, PhD
University of Munich
Munich, Germany
Andreas Engert, MD
University Hospital of Cologne
Cologne, Germany
Massimo Federico, MD
di Modena e Reggio Emilia
Modena, Italy.
Pierre Fenaux, MD, PhD
Hôpital Avicenne
Université Paris 13
Bobigny, France
Ulrich Germing, MD
Heinrich-Heine-University Düsseldorf
Dusseldorf, Germany
Paolo Ghia, MD, PhD
Università Vita-Salute San Raffaele
San Raffaele
Scientific Institute
Milan, Italy
Hans Hagberg, MD
Academic Hospital
Uppsala, Sweden
Eva Hellstrom-Lindberg, MD, PhD
Karolinska Institute
Huddinge University Hospital
Stockholm, Sweden
Wolfgang Hiddemann, MD, PhD
University of Munich
Munich, Germany
Dieter Hoelzer, MD, PhD
J.W. Goethe University Hospital
Institute for Hematology
Frankfurt, Germany
Tim M. Illidge, MD, PhD, FRCR, FRCP
Christie Hospital
Manchester University
Manchester, United Kingdom
Eva Kimby, MD, PhD
Karolinska Institute
Huddinge University Hospital
Stockholm, Sweden
Veronique LeBlond, MD
Hopital Pitie-Salpetriere
Paris, France
Luca Malcovati, MD
University of Pavia Medical School
S. Matteo University Hospital
Pavia, Italy
Emilio Montserrat, MD
Hospital Clinic University of Barcelona
Barcelona, Spain
Owen A. O'Connor, MD, PhD
Columbia University
Herbert Irving Comprehensive Cancer Center
New York, New York, United States
Antonio Palumbo, MD
University of Torino
Torino, Italy
Jürgen Rademaker, MD
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Andreas Rosenwald, MD
University of Würzburg
Würzburg, Germany
Norbert Schmitz, MD, PhD
Asklepios Klinik St. Georg
Hamburg, Germany
Jörg Schubert, MD
Saarland University Medical School
Homburg, Germany
Anas Younes, MD
The University of Texas
MD Anderson
Houston, Texas, United States
Emanuele Zucca, MD
IOSI Oncology Institute of Southern Switzerland
Bellinzona, Switzerland
Friday, 13 February 2009
13:00
Welcome and introduction
Session I: Myeloma
Moderator: Kenneth C. Anderson, MD, MA
13:05
Oncogenomics to target myeloma in the bone marrow microenvironment
Kenneth C. Anderson, MD
13:25
Debate: What is the optimal management of newly diagnosed patients?
Proteasome inhibitors: Speaker invited
IMiDs compounds: Meletios A. Dimopoulos, MD
13:55
Autotransplant: First line or relapse?
Speaker invited
14:15
Options for relapsed/refractory multiple myeloma
Speaker invited
14:35
The role of VTE prophylaxis
Antonio Palumbo, MD
14:55
Panel discussion and session chair take-home points for the clinician
15:05
Coffee break
Session II: Indolent Lymphomas and Related Diseases
Moderator: Eva Kimby, MD, PhD
15:30
MALT lymphoma: From biology to treatment
Emanuele Zucca, MD
15:50
Waldenstrom’s macroglobulinemia
Eva Kimby, MD, PhD
16:10
Optimal therapy in first line mantle cell lymphoma
Martin Dreyling, MD, PhD
16:30
Autoimmune disorders and CLL
Federico Caligaris-Cappio, MD
16:50
Panel discussion and session chair take-home points for the clinician
17:00
Chair summary and adjourn
Saturday, 14 February 2009
Session III: Chronic Lymphocytic Leukemia
Moderator: Speaker invited
9:00
New prognostic indicators
Paolo Ghia, MD, PhD
9:20
Clinical trial update: Front-line management of CLL
Speaker invited
9:40
Treatment options for relapsed/refractory CLL
Véronique LeBlond, MD
10:00
Richter's syndrome
Emilio
Montserrat, MD
10:20
Novel agents in CLL
Speaker invited
10:40
Panel discussion and session chair take-home points for the clinician
10:50
Coffee break
Session IV: Follicular Lymphoma
Moderator: Eva Kimby, MD, PhD
11:10
Biology of follicular lymphoma
Daphne de Jong, MD, PhD
11:30
First line treatment of patient with aggressive follicular lymphoma
Speaker invited
11:50
The role of radioimmunotherapy in follicular lymphoma
Timothy M. Illidge, MD, PhD, FRCR, FRCP
12:10
Options for relapsed/refractory follicular lymphoma in the rituximab era
Bertrand Coiffier, MD
12:30
Autologous transplant in the era of rituximab
Wolfgang Hiddemann, MD, PhD
12:50
Panel discussion and session chair take-home points for the clinician
13:00
Lunch break
Saturday, 14 February 2009 (...cont'd)
Session V: Aggressive NHL
Moderator: Bertrand Coiffier, MD
14:30
Interest of gene expression profiling in DLBCL
Andreas Rosenwald, MD
14:50
Novel regimens in molecular targeting of aggressive lymphomas
Anas Younes, MD
15:10
Radiation therapy in DLBCL (localized and disseminated)
Jörg Schubert, MD
15:30
Treatment of Burkitt lymphoma/leukemia in young adults
Dieter Hoelzer, MD, PhD
15:50
Panel discussion and session chair take-home points for the clinician
16:00
Coffee break
Session VI: T Cell Lymphoma
Moderator: Owen A. O’ Connor, MD, PhD
16:20
Angioimmunoblastic lymphadenopathy: Biology and treatment
Massimo Federico, MD
16:40
Front-line treatment of T cell lymphoma
Hans Hagberg, MD
17:00
Targeted agents in T cell lymphoma
Owen A. O’ Connor, MD, PhD
17:20
Allogeneic transplant in T-cell lymphoma
Norbert Schmitz, MD, PhD
17:40
Panel discussion and session chair take-home points for the clinician
17:50
Adjourn
Sunday, 15 February 2009
Session VII: Hodgkin’s Disease
Moderator: Volker Diehl, MD, PhD
9:00
Radiologic evaluation of early stage Hodgkin's disease
Jürgen Rademaker, MD
9:20
Molecules and antibodies: Hype or hope for Hodgkin’s disease?
Andreas Engert, MD
9:40
Optimal treatment for relapsing patients with Hodgkin’s disease
Speaker invited
10:00
Clinical trials in Hodgkin’s: Update and future directions
Volker Diehl, MD, PhD
10:20
Panel discussion and session chair take-home points for the clinician
10:30
Coffee break
Session VIII: SPECIAL SESSION – Myelodysplastic Syndromes
Moderator: Eva Hellstrom-Lindberg, MD, PhD
11:00
WHO 2008 classification of MDS and mixed MDS/MPD
Ulrich Germing, MD
11:20
Prognosis and risk assessment in MDS
Luca Malcovati, MD
11:40
Pathogenetic mechanisms in MDS
Simone Boehrer, MD
12:00
Current and future treatment of low-risk MDS including 5q- syndrome
Eva Hellström-Lindberg, MD, PhD
12:30
Current and future treatment of high-risk MDS including SCT
Pierre Fenaux, MD, PhD
13:00
Panel discussion and take home message
13:10
Adjourn
Registration Fees
Regular . . . . . . . . . . . . . . . . . . . . . . €399
If payment received by 5 February 2009
Full/Onsite . . . . . . . . . . . . . . . . . . . .€499
If payment received after 5 February 2009
Nurses/Residents/Students* . . . . . . . €199
*proof of eligibility must accompany registration
To Register:
You may register online by 5 February 2009 or by calling Imedex at +1 (678) 242 0906. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.
Payment:
To pre-register, registration and payment must be received no later than 5 February 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the program is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card, check, or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add €50 to each wire transaction to cover bank charges. Include the full name of the attendee and the name of the Congress: EHema A064.01. An attendee is not registered until full payment is received.
Wire to: Bank of America, NA London, 1 Alie Street E1ADE London UK, Swift Code: BOFAGB22, Sort Code: 165050 Beneficiary: Bank of America Domestic Deposit #5687, Account #: 600895687029, Reference: Imedex, Inc. Account # 10726-118, IBAN: GB89 BOFA 1650 5095 6870 29.
Registration Fee Inclusions:
Registration fees include admittance to all scientific sessions, Congress materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.
Cancellation:
For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than 5 February 2009. The amount of registration fees remitted, minus a €90 administrative charge, will be refunded after the Congress. Substitutions are accepted with written notification. No refunds will be made if notice is received after 5 February 2009.
Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this Congress should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.
Arabella Sheraton Grand Hotel
Arabellastrasse 6
81925 Munich, Germany
Tel.: +49 0 89 92 64 8604
Fax: +49 0 89 92 64 8009
One of the most inviting grand hotels in Europe, the Arabella Sheraton Grand Hotel München unites traditional and modern appeal. The guest rooms offer a panoramic view of Munich and beyond to the Alps. You are sure to feel at home in their stylish and comfortable décor. The hotel is located in the prestigious Munich district of Bogenhausen in the exclusive Arabellapark. Explore the local shops and boutiques and enjoy fine dining at local restaurants. Munich’s famous park, the English Garden, with its beer gardens and long walking trails, is only a few hundred meters away and the city centre and central station are 10 minutes away by underground train.
For the convenience of attendees, a limited number of rooms have been reserved until 12 January 2009 at a discounted rate of €149.00 single occupancy or €176.00 double occupancy for the executive category of room. Room rates include 19% VAT and breakfast buffet. This rate is not guaranteed outside the Congress dates or after 12 January 2009.
To reserve your room please contact the Arabella Sheraton Grand Hotel München reservations department at +0049 89 93001 6396 or visit the hotel’s website at http://www.starwoodmeeting.com/Book/imedexmunich. To receive the group rate, callers must identify themselves as being with the 5th European Congress on Hematologic Malignancies group. Reservation requests received after 12 January 2009 may not be guaranteed the group rate.
Invitation
Dear Colleague,
We are pleased to invite you to attend the 5th European Congress on Hematologic Malignancies: From Clinical Science to Clinical Practice, which will be held 13-15 February 2009, in beautiful and historic Munich, Germany! The focus of this Congress is to provide a forum to review state-of-the-art and present new data on the diagnosis and management of myeloma, lymphoma and other hematologic disorders such as MDS as well as give attendees the opportunity to exchange ideas with world-renowned opinion leaders.
Last year’s Congress, held in Paris, France, was attended by more than 500 hematologists and oncologists from 48 countries, most of whom are directly involved in patient care. Their highly positive review of the educational content, quality of the speakers, and presentation excellence attests to the overall satisfaction of the attendees and the value of continuing with a comprehensive update on hematologic oncology management.
To complement the exceptional scientific experience this Congress brings, Munich offers the perfect setting for enjoyable after-hours relaxation. There are few cities that can compete with the history, charm, arts and dining experiences that Munich has to offer. We hope you will join us in this beautiful and historic city for a stimulating and enjoyable Congress.
Sincerely,
Bertrand Coiffier, MD
Eva Kimby, MD, PhD
Praise from Past Participants:
“Conference hard to improve – it was very good”
“I found this meeting very enjoyable”
“Excellent conference”
“Thank you…interesting meeting”
“Keep up the good work”
“Thank you very much to Imedex”
“Continue in the same way!”
“Well organized”
“Thank you for high quality symposium”
Organizer:
Imedex
4325 Alexander Drive
Alpharetta, GA 30022-3740, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com
Chairs:
Bertrand Coiffier, MD
Hospices Civils de Lyon
Lyon, France
Eva Kimby, MD, PhD
Karolinska Institute
Huddinge University Hospital
Stockholm, Sweden
Local Chair:
Wolfgang Hiddemann, MD, PhD
University of Munich
Munich, Germany
Important Dates:
Regular Registration Deadline
5 February 2009
Presentation Dates
13-15 February 2009
Congress Location:
Arabella Sheraton Grand Hotel
Arabellastrasse 6
81925 Munich, Germany
Tel.: +49 0 89 92 64 8604
Fax: +49 0 89 92 64 8009
Italian Participants:
Fargo International Meetings & Conventions SRL has been appointed as the
official agency for government authorization for Italian participants.
You may contact them directly at:
Fargo International Meetings & Conventions SRL
Via Piattro Maroncelli 44/66, 50137 Firenze, Italy
Tel.: +39 055 600 555
Fax: +39 055 609 078
Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.
In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.
©2009 Imedex®, LLC. All rights reserved.
Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.
Founding Supporter
Bronze
Millennium Pharmaceuticals, Inc.
Corporate
Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.